Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeoPharm Files ODA For IL13-PE38QQR
Orphan drug designation provides a seven-year term of market exclusivity for IPF upon final FDA approval. Orphan drug designation would position NeoPharm to be able to take advantage
Orphan drug designation provides a seven-year term of market exclusivity for IPF upon final FDA approval. Orphan drug designation would position NeoPharm to be able to take advantage
The patent entitled ‘Sustained-Release Bupropion and Bupropion/Mecamylamine Tablets’ discloses the formulation of pharmaceutical tablets containing sustained-release granules of Bupropion HCl distributed in a sustained-release matrix. The patent will
The agreement includes a requirement for Stason to purchase a minimum of one million units of the Unitract 1mL syringe per year during the term of the contract
Under the terms of the agreement, BioInvent will apply its antibody discovery technology to generate and develop monoclonal antibody candidates. The collaboration will initially focus on the development
As per the agreement, Torrent will provide AstraZeneca with a portfolio of generic medicines for which the Indian group already has licenses in a range of countries, starting
Brentuximab vedotin, an ADC that utilises the vcMMAE drug-linker unit, is in a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for relapsed
Laxai said that the acquisition has been completed for $3.6m consisting of $1.5mm in cash, $0.75mm in notes, $0.60mm in assumed liabilities, and 5.6mm common shares of Laxai
Prialt, a non-opioid analgesics, works by targeting and blocking N-type calcium channels on nerves in the spinal cord that ordinarily transmit pain signals. It has been evaluated as
The injections, which are therapeutically equivalent to Eloxatin from Sanofi-Aventis, received approval from the FDA for Sun Pharma’s abbreviated new drug application (ANDA). Eloxatin is a registered trademark
The four-year agreement includes some minimum purchases and may be extended through mutual consent. Stephen Beatty, president and CEO of Helix BioMedix, said: “RubyDerm Bio gives the Company